Project Grant R03AI193602
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$151K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $537,619 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida Board of Trustees Office of Research. The grant supports the development of a single biosensor platform for the simultaneous molecular detection of HIV, hepatitis B, and hepatitis C viruses, targeted for use in resource-limited settings. The project leverages the university's expertise in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a 5-year, $1,361,442 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to develop an economical, rapid molecular test for detecting hepatitis C virus (HCV) and HIV. The key objectives are: Adapt and automate RNA sample extraction and stabilization technology to enable HCV/HIV RNA extraction from capillary whole blood. This includes creating a sample-in, RNA-out device using...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $314,363 Project Grant to Priogen Corp to develop a microfluidic device for the rapid detection of infectious prion proteins. The device, called Micro-QUIC, leverages acoustic wave technology and fluorescent dyes to detect misfolded prion proteins that cause fatal neurodegenerative disorders like Creutzfeldt-Jakob disease (CJD) and bovine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,178,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant, which runs from August 20, 2024 to July 31, 2025, is for developing a "tunable nanophage platform" to rapidly screen and formulate multi-antigen vaccine candidates against emerging infectious disease threats like SARS-CoV-2 variants and pre-emergent SARS-like...
This $453,900 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is funding research to develop a genome editing platform using broadly functioning phage recombinases, which can be used to genetically manipulate a wide range of bacterial species, including clinically relevant pathogens. The goal is to enable direct investigation of the genetic elements driving bacterial...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,269,762 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University. The grant will fund the development of a microfluidic platform called SECRE (Secretion-Enabled Cell Ranking and Enrichment) to enable high-performance sorting of immune cells based on their secretion patterns. This technology will be leveraged to conduct genome-wide CRISPR activation and/or...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $504,703 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Georgia Research Foundation, Inc. The grant aims to further optimize and integrate a novel ultra-sensitive PCR (UltraPCR) method for detecting and quantifying Trypanosoma cruzi, the parasite that causes Chagas disease. The goal is to develop this UltraPCR platform as a confirmatory diagnostic test and to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $92,809,964 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB) on July 30, 2024. The PARAMYXOVIRIDAE AND BUNYAVIRALES VACCINES AND ANTIBODIES CENTER (PABVAX) project will focus on developing, testing, and translating prototype subunit vaccines using a novel microneedle patch platform, as well as developing new...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
This $900,000 Project Grant was awarded on September 1, 2024 by the National Institute of Standards and Technology (NIST) under the Congressionally-Identified Projects (CFDA 11.617) program. The grant's purpose is to procure research equipment needed to establish the Pathogen Research and Surveillance Laboratory at the University of Central Florida (UCF). Specifically, the grant will enable UCF to purchase automated sample preparation and next-generation genomic sequencing equipment. This...